

Alice Ferretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9201976/publications.pdf>

Version: 2024-02-01

39
papers

918
citations

471061

17
h-index

454577

30
g-index

39
all docs

39
docs citations

39
times ranked

1406
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and Imaging with Leak Microstructures. <i>Instruments</i> , 2021, 5, 15.	0.8	0
2	A new mobile self-dispensing and administering system for 18F-FDG: evaluation of operator dose reduction. <i>Journal of Radiological Protection</i> , 2020, 40, 243-252.	0.6	1
3	Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes. <i>Drug Delivery and Translational Research</i> , 2019, 9, 123-130.	3.0	59
4	Technetium-99m-labeled lapachol as an imaging probe for breast tumor identification. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2019, 38, 167-172.	0.1	3
5	How to harmonize SUVs obtained by hybrid PET/CT scanners with and without point spread function correction. <i>Physics in Medicine and Biology</i> , 2018, 63, 235010.	1.6	12
6	Sentinel lymph node biopsy in small papillary thyroid cancer. A review on novel surgical techniques. <i>Endocrine</i> , 2018, 62, 340-350.	1.1	30
7	FDG PET/CT in Aortic Valve Bioprosthesis Infection. <i>Clinical Nuclear Medicine</i> , 2017, 42, e347-e348.	0.7	3
8	Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 146-151.	2.5	23
9	Catecholamine-Induced Chest Pain Mimicking Infarction Due to an MIBG-Negative and DOPA-Positive Succinate Dehydrogenase Syndrome Subunit B-Related Pheochromocytoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 489-491.	0.7	0
10	18F-DOPA PET/CT in the Evaluation of Hereditary SDH-Deficiency Paraganglioma-Pheochromocytoma Syndromes. <i>Clinical Nuclear Medicine</i> , 2014, 39, e53-e58.	0.7	20
11	Biological Target Volume Overlapping Segmentation System Method for Avoiding False-Positive PET Findings in Assessing Response to Neoadjuvant Chemoradiation Therapy in Rectal Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e215-e219.	0.7	9
12	Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1293-1300.	3.3	25
13	Endocrine Scintigraphy with Hybrid SPECT/CT. <i>Endocrine Reviews</i> , 2014, 35, 717-746.	8.9	14
14	Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1356-1364.	3.3	43
15	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1190-1196.	3.3	63
16	Usefulness of 11C-Choline Positron Emission Tomography for Genital Chlamydial Infection Assessment in a Balb/c Murine Model. <i>Molecular Imaging and Biology</i> , 2013, 15, 450-455.	1.3	3
17	The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 172-178.	2.5	10
18	Proton Magnetic Resonance Spectroscopy: Ex vivo study to investigate its prognostic role in colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 593-597.	2.5	4

#	ARTICLE	IF	CITATIONS
19	Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 853-864.	3.3	63
20	18F-FDG-PET/CT in malignant mesothelioma. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 539-542.	2.5	9
21	Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 533-538.	2.5	5
22	Phantom study of a new hand-held $\hat{1}^3$ -imaging probe for radio-guided surgery. <i>Nuclear Medicine Communications</i> , 2013, 34, 86-90.	0.5	17
23	Medical professional values and education: A survey on Italian students of the medical doctor school in medicine and surgery. <i>North American Journal of Medical Sciences</i> , 2013, 5, 134.	1.7	6
24	Proposal of a New 18F-FDG PET/CT Predictor of Response in Rectal Cancer Treated by Neoadjuvant Chemoradiation Therapy and Comparison With PERCIST Criteria. <i>Clinical Nuclear Medicine</i> , 2013, 38, 795-797.	0.7	21
25	11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e279-e282.	0.7	14
26	Parathyroid Scintigraphy in Renal Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2013, 38, 630-635.	0.7	47
27	The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level $\hat{1}^3$ 0.5 ng/mL. <i>Clinical Nuclear Medicine</i> , 2013, 38, e342-e345.	0.7	63
28	Intraoperative Hand-Held Imaging $\hat{1}^3$ -Camera for Sentinel Node Detection in Patients With Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, e132-e136.	0.7	14
29	The PERCIST criteria. <i>Nuclear Medicine Communications</i> , 2013, 34, 619-620.	0.5	9
30	Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy. <i>Clinical Nuclear Medicine</i> , 2013, 38, e26-e32.	0.7	72
31	Aggressive Papillary Thyroid Microcarcinoma. <i>Clinical Nuclear Medicine</i> , 2013, 38, 25-28.	0.7	79
32	Correlative Imaging With 18F-FDG PET/CT and MRI in Paraneoplastic Limbic Encephalitis. <i>Clinical Nuclear Medicine</i> , 2013, 38, 463-464.	0.7	8
33	99mTc-MAG3 Diuretic Renography in Diagnosis of Obstructive Nephropathy in Adults. <i>Clinical Nuclear Medicine</i> , 2013, 38, 432-436.	0.7	14
34	Optimising $\hat{1}^8$ -F-choline PET/CT acquisition protocol in prostate cancer patients. <i>North American Journal of Medical Sciences</i> , 2012, 4, 416.	1.7	28
35	18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2012, 33, 179-184.	0.5	33
36	A new methodological approach for PET implementation in radiotherapy treatment planning. <i>Nuclear Medicine Communications</i> , 2012, 33, 516-520.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Early bone marrow metastasis detection: The additional value of FDG-PET/CT vs. CT imaging. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 448-453.	2.5	50
38	Phantom study of the impact of reconstruction parameters on the detection of mini- and micro-volume lesions with a low-dose PET/CT acquisition protocol. <i>European Journal of Radiology</i> , 2012, 81, 3363-3370.	1.2	9
39	Tumour-localizing and -photosensitising properties of meso-tetra(4-nido-carboranylphenyl)porphyrin (H2TCP). <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2007, 89, 131-138.	1.7	32